<p>Pharmaceuticals firm Novartis India on Thursday reported a 43 per cent increase in net profit at Rs 9.7 crore for the fourth quarter ended March 31, 2021.</p>.<p>The company had posted a net profit of Rs 6.78 crore in the same quarter of the previous fiscal, Novartis India said in a regulatory filing.</p>.<p>Revenue from operations stood at Rs 99.29 crore as compared to Rs 93.7 crore in the year-ago quarter.</p>.<p>Total expenses in the fourth quarter were marginally higher at Rs 89.66 crore as against Rs 88.09 crore earlier, the company said.</p>.<p>For the full fiscal 2020-21, the company said its net profit jumped over two-fold to Rs 20.9 crore from Rs 10.08 crore in 2019-20.</p>.<p>Revenue from operations for FY21 stood at Rs 381.35 crore as against Rs 438.25 crore in FY20.</p>.<p>The board of directors of the company has recommended a 200 per cent dividend of Rs 10 per share of Rs 5 each for the year ended March 31, 2021, Novartis India said.</p>.<p>During the quarter and the year ended March 31, 2021 the company continued to ensure uninterrupted supply of its products, it said, adding the impact assessment of Covid-19 is a continuing process given the uncertainties associated with its nature and duration.</p>.<p>"The company will continue to monitor any material changes to future economic conditions," it added.</p>
<p>Pharmaceuticals firm Novartis India on Thursday reported a 43 per cent increase in net profit at Rs 9.7 crore for the fourth quarter ended March 31, 2021.</p>.<p>The company had posted a net profit of Rs 6.78 crore in the same quarter of the previous fiscal, Novartis India said in a regulatory filing.</p>.<p>Revenue from operations stood at Rs 99.29 crore as compared to Rs 93.7 crore in the year-ago quarter.</p>.<p>Total expenses in the fourth quarter were marginally higher at Rs 89.66 crore as against Rs 88.09 crore earlier, the company said.</p>.<p>For the full fiscal 2020-21, the company said its net profit jumped over two-fold to Rs 20.9 crore from Rs 10.08 crore in 2019-20.</p>.<p>Revenue from operations for FY21 stood at Rs 381.35 crore as against Rs 438.25 crore in FY20.</p>.<p>The board of directors of the company has recommended a 200 per cent dividend of Rs 10 per share of Rs 5 each for the year ended March 31, 2021, Novartis India said.</p>.<p>During the quarter and the year ended March 31, 2021 the company continued to ensure uninterrupted supply of its products, it said, adding the impact assessment of Covid-19 is a continuing process given the uncertainties associated with its nature and duration.</p>.<p>"The company will continue to monitor any material changes to future economic conditions," it added.</p>